**Question:** rtPA is NOT a contraindication in stroke with

A. Age over 80 years
B. Intracranial haemorrhage
C. Large vessel occlusion
D. Contraindications for IV thrombolysis

**Core Concept:**

Alteplase (rtPA), a recombinant tissue plasminogen activator, is a drug used for thrombolysis, the breakdown of blood clots, in acute ischemic stroke patients. The goal is to restore blood flow to the affected brain tissue and minimize infarction (brain tissue damage). However, there are certain conditions that make a patient unsuitable for rtPA administration, which are referred to as its contraindications.

**Why the Correct Answer is Right:**

rtPA is not contraindicated in stroke patients with:

Option A (Age over 80 years):
While advanced age is a risk factor for stroke and may impact treatment outcomes, it is not explicitly listed as a contraindication for rtPA therapy. The decision to administer rtPA should be based on the patient's stroke severity, functional status, and the potential benefits versus risks.

Option B (Intracranial haemorrhage):
Intracranial haemorrhage refers to bleeding within the brain. In this context, rtPA is contraindicated in subarachnoid haemorrhage and intracerebral haemorrhage because of the risk of increasing the risk of haemorrhagic conversion, where a previously ischemic stroke evolves into a haemorrhagic stroke.

Option C (Large vessel occlusion):
Large vessel occlusion involves a blockage in the major cerebral vessels, such as the internal carotid artery or M1 segment of the middle cerebral artery. While large vessel occlusion is a severe stroke type involving a higher risk of haemorrhagic conversion when treated with rtPA, it is not explicitly stated as a contraindication for rtPA therapy. The decision to administer rtPA should be based on the patient's stroke severity, functional status, and the potential benefits versus risks.

Option D (Contraindications for IV thrombolysis):
Contraindications for intravenous thrombolysis include:

1. **Major bleeding or coagulopathy (e.g., platelet count 1.5).**
2. **Subarachnoid haemorrhage.**
3. **Stroke within the past 3 hours.**
4. **Hypersensitivity to rtPA.**
5. **Active bleeding disorder or recent surgery.**
6. **Pregnancy.**

**Why Each Wrong Option is Wrong:**

Option A (Age over 80 years): Contraindications in this category are primarily focused on the risk of haemorrhagic conversion and poor outcomes in older patients. While age is a risk factor, it is not explicitly listed as a contraindication for rtPA therapy.

Option B (Subarachnoid haemorrhage): Subarachnoid haemorrhage is a major contraindication for rtPA therapy due to the risk of haemorrhagic conversion.

Option